SequelSEC

CUMBERLAND PHARMACEUTICALS INC CPIX

Pharmaceutical Preparations · CIK 0001087294 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$166.46K
Fiscal year ended 2026-06-30
Operating income
-$3.16M
Fiscal year ended 2026-06-30
Free cash flow
$130.46K
Fiscal year ended 2026-06-30

CUMBERLAND PHARMACEUTICALS INC (CPIX) reported revenue of $166.46K and net income of -$4.28M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from CUMBERLAND PHARMACEUTICALS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CUMBERLAND PHARMACEUTICALS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$166.46K$9.13M$13.68M$8.29M$380.80K$11.71M$10.44M$9.09M$9.85M$8.50M
Cost of revenueUnavailable$1.93M$2.24M$988.76K$2.01M$1.43M$1.98M$1.32M$1.71M$1.58M
Gross profitUnavailable$7.20M$11.44MUnavailableUnavailable$10.29M$8.46MUnavailableUnavailableUnavailable
Operating income-$3.16M-$3.13M-$1.37M-$1.97M-$3.12M$1.29M-$1.84M-$1.69M-$1.03M-$1.87M
Net income-$4.28M-$3.29M-$1.41M-$1.94M-$740.74K$1.26M-$1.90M-$1.54M-$1.09M-$1.95M
Research & development$772.16K$1.46M$1.55M$1.25M$837.40K$1.30M$1.29M$1.31M$1.06M$1.16M
Weighted-average diluted sharesshares 14.98Mshares 14.96MUnavailableshares 14.96Mshares 14.96Mshares 15.26MUnavailableshares 14.05Mshares 14.12Mshares 14.10M
Pretax income-$3.10M-$3.14MUnavailable-$1.94M-$2.99M$1.25M-$1.96M-$1.53M-$1.09M-$1.89M
Income tax expense$3.87K$3.87K$23.24K$5.67K$5.67K$5.67K-$57.00K$11.44K$11.44K$11.44K
Diluted EPS$-0.29$-0.22$-0.09$-0.13$-0.05$0.08$-0.14$-0.11$-0.08$-0.14
Selling, general & administrativeUnavailable$7.62M$10.25M$7.01MUnavailable$6.69M$7.55M$7.07M$7.01M$6.52M
General & administrative$2.55M$2.55M$4.04M$2.57M$2.66M$2.46M$3.33M$2.68M$2.76M$2.37M
Selling & marketingUnavailable$5.06M$6.21M$4.43M$4.22M$4.23M$4.22M$4.40M$4.25M$4.15M

Balance

CUMBERLAND PHARMACEUTICALS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$3.86M$11.01M$11.44M$15.20M$16.09M$15.11M$17.96M$17.46M$17.34M$18.55M
Total assets$62.88M$71.00M$76.82M$65.90M$67.91M$69.94M$75.58M$76.75M$78.52M$81.51M
Current assets$33.64M$32.79M$37.06M$29.94M$31.21M$31.88M$36.45M$35.24M$35.58M$36.21M
Total liabilities$45.77M$49.69M$52.28M$40.10M$40.23M$41.60M$53.04M$52.28M$52.49M$54.32M
Current liabilities$35.19M$34.49M$36.74M$24.31M$23.97M$25.52M$31.62M$31.09M$24.76M$26.43M
Total equity incl. NCI$17.11M$21.30M$24.54M$25.80M$27.68M$28.34M$22.55M$24.47M$26.03M$27.19M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$29.94K$5.45M$29.94K$2.93M$3.22M$4.10M$4.00M$4.51M$4.30M$4.33M
Accounts receivable$13.42M$14.26M$16.94M$10.43M$10.32M$10.49M$11.70M$11.31M$11.62M$10.65M
GoodwillUnavailable$914.00K$914.00K$914.00K$914.00K$914.00K$914.00K$914.00K$914.00K$914.00K
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$19.55M$16.54M$18.57M$13.83M$13.45M$13.93M$13.91M$12.06M$12.51M$13.08M

Cash flow

CUMBERLAND PHARMACEUTICALS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$168.74K$387.02K$3.02K$187.18K$843.80K$3.90M$1.90M$475.50K-$855.66K-$2.14M
Capital expenditures$38.28K$0-$1$23.79K$26.49K$47.63K$2.28K$15.38K$7.18K$41.62K
Investing cash flow-$1.93M-$61.17K-$3.07M-$690.84K$285.86K-$1.23M-$26.81K$189.64K-$46.80K-$58.19K
Financing cash flow-$5.39M-$763.30K-$681.74K-$386.88K-$150.80K-$5.53M-$1.38M-$536.84K-$309.58K$2.42M
Net change in cash-$7.14M-$437.45K-$3.75M-$890.54K$978.87K-$2.86M$499.43K$128.31K-$1.21M$226.86K
Stock-based compensation$77.87K$106.84K$172.16K$81.26K$80.69K$74.21K$74.81K$76.37K$71.96K$78.75K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$61.00K$0$10.44K$7.17K$245.87K$98.38K$98.82K$134.25K$247.60K
Depreciation & amortization-$1.20M$1.28M$1.04M$3.03M-$953.82K$1.03M$1.50M$1.12M$1.14M$1.15M

Derived

CUMBERLAND PHARMACEUTICALS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$130.46K$387.02KUnavailable$163.39K$817.32K$3.85M$1.90M$460.12K-$862.84K-$2.18M
Gross marginUnavailable78.8%83.6%UnavailableUnavailable87.8%81.1%UnavailableUnavailableUnavailable
Operating margin-1898.7%-34.3%-10.0%-23.7%-819.2%11.0%-17.7%-18.6%-10.4%-22.0%
FCF margin78.4%4.2%Unavailable2.0%214.6%32.9%18.2%5.1%-8.8%-25.6%
SBC / revenue46.8%1.2%1.3%Unavailable21.2%0.6%0.7%UnavailableUnavailableUnavailable
Current ratio0.96x0.95x1.01x1.23x1.30x1.25x1.15x1.13x1.44x1.37x
Revenue YoY growth-56.3%-22.0%31.1%-8.7%-96.1%37.8%11.6%-9.9%-9.6%-7.9%
Net margin-2569.0%-36.0%-10.3%-23.4%-194.5%10.7%-18.2%-17.0%-11.0%-22.9%
R&D / revenue463.9%16.0%11.3%Unavailable219.9%11.1%12.4%UnavailableUnavailableUnavailable
CapEx / revenue23.0%0.0%-0.0%Unavailable7.0%0.4%0.0%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable0.5%UnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CPIX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Reconciliation checks needing review

9 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.